Join

Compare · BHG vs NTRA

BHG vs NTRA

Side-by-side comparison of Bright Health Group Inc. (BHG) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BHG and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
  • NTRA is the larger of the two at $30.57B, about 18.3x BHG ($1.67B).
  • NTRA has hit the wire 16 times in the past 4 weeks while BHG has been quiet.
  • Both have 25 recent analyst ratings on file.
MetricBHGNTRA
Company
Bright Health Group Inc.
Natera Inc.
Price
$14.94+43.65%
$213.41-0.88%
Market cap
$1.67B
$30.57B
1M return
-
-2.79%
1Y return
-
+30.09%
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2021
2015
News (4w)
0
16
Recent ratings
25
25
BHG

Bright Health Group Inc.

Bright Health Group, Inc., an integrated care delivery company, engages in the delivery and financing of health insurance plans in the United States. It operates in two segments, NeueHealth and Bright HealthCare. The company offers individual and family, Medicare, and employers insurance plans. It also operates 28 managed and affiliated risk-bearing primary care clinics. The company was formerly known as Bright Health Inc. and changed its name to Bright Health Group, Inc. in February 2021. Bright Health Group, Inc. was incorporated in 2015 and is based in Minneapolis, Minnesota.

NTRA

Natera Inc.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Latest BHG

Latest NTRA